MADIA will develop a versatile and cost-effective in-vitro tool for early diagnosis of Alzheimer’s and Parkinson’s diseases. Alzheimer’s and Parkinson’s diseases, the two most common neurodegenerative disorder worldwide, are debilitating and largely untreatable conditions that are strongly linked with age.

The project  aims at fabricating devices based on arrays of magnetic sensors integrated into a microfluidics device and capable of recognising biomarkers, obtained from cerebrospinal fluid or blood samples, conjugated with ultra-small magnetic nanoparticles.

This will allow the early diagnosis of Alzheimer’s and Parkinson’s diseases and improve the efficacy of current therapies which have been shown to slow the progression, particularly of Parkinson’s disease, as currently there is no cure for either disease.

Within the MADIA project Orthokey will leverage its expertise in software design and develop for workflow management of the whole process.

For more information on MADIA, please visit http://www.madia-project.eu/